The new international neuroblastoma response criteria.

Katharine E Orr, Kieran McHugh

Journal: Pediatric radiology 2020;49(11):1433-1440

PMID: 31620844

Abstract

Over recent years significant advances in histopathology and functional imaging techniques for the diagnosis and restaging of children with neuroblastoma have led to better quantification of disease and assessment of disease response, allowing for better treatment stratification. In this review we summarise recent changes to the International Neuroblastoma Response Criteria including the use of RECIST (Response Evaluation Criteria in Solid Tumours) guidance for measurable soft-tissue disease, replacement of technetium-99 m-methylene diphosphonate (MDP) bone scans with metaiodobenzylguanidine (MIBG) scan or [F-18]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET)/CT scanning, and a new category of minimal residual bone marrow disease.

Address: Department of Paediatric Radiology, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London, WC1N 3JH, UK. [email protected].; Department of Radiology, Evelina London Children's Hospital, London, UK. [email protected].; Department of Paediatric Radiology, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London, WC1N 3JH, UK.

DOI: 10.1007/s00247-019-04397-2

Link outs

Free resources

Medical:

https://medlineplus.gov/neuroblastoma.html

Subscription / membership required

Full Text Sources:

https://dx.doi.org/10.1007/s00247-019-04397-2

MeSH Terms: 3-Iodobenzylguanidine, Bone Marrow Neoplasms, Bone Neoplasms, Child, Humans, Iodine Radioisotopes, Neoplasm, Residual, Neuroblastoma, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals, Response Evaluation Criteria in Solid Tumors, Soft Tissue Neoplasms